Table 1.
Baseline characteristics of enrolled patients.
| Characteristics | n = 40 |
|---|---|
| Age (years, range) | 70.5 (53–82) |
| Sex (male/female) | 35/5 |
| Etiology (HBV/HCV/non-B non-C) | 6/13/21 |
| BCLC stage (B/C) | 21/19 |
| Treatment history (naïve/recurrence) Treatment prior to Atezo/Bev Surgery TACE Lenvatinib Sorafenib Regorafenib Ramucirumab Radiation therapy |
6/34 7 11 11 2 1 1 1 |
| Aspartate aminotransferase (IU/L) | 39.5 (15–192) |
| Alanine aminotransferase (IU/L) | 28.0 (11–110) |
| Platelets (×104/μL) | 14.4 (4.2–28.1) |
| Child-Pugh score (5A/6A/7B) | 26/12/2 |
| ALBI score | −2.53 (−3.16–−1.45) |
| Modified ALBI grade (1/2a/2b) | 16/12/12 |
| α-fetoprotein (ng/mL) | 19.0 (1.4–57063) |
| Des-γ-carboxy prothrombin (mAU/mL) | 136 (12–177443) |
| FIB-4 index | 3.57 (1.49–11.7) |
| Neutrophil-to-lymphocyte ratio (NLR) | 2.56 (0.39–14.0) |
| Platelet-to-lymphocyte ratio (PLR) | 125 (27.1–351) |
| Lymphocyte-to-monocyte ratio (LMR) | 2.79 (0.86–5.41) |
HBV, hepatitis B virus; HCV, hepatitis C virus; BCLC, Barcelona Clinic Liver Cancer; Atezo/Bev, atezolizumab plus bevacizumab; TACE, transarterial chemoembolization; ALBI, albumin-bilirubin; AU, arbitrary unit; FIB-4, fibrosis-4. Values are presented as median (range) or number.